Lineage Q4 2019 Earnings Report
Key Takeaways
Lineage Cell Therapeutics reported Q4 2019 revenues of $1.2 million, an increase of $0.4 million compared to 2018. The net loss attributable to Lineage for the quarter was $4.5 million, or $0.03 per share, compared to a net loss of $45.0 million, or $0.35 per share, for the same period in 2018.
Established Lineage as a leading cell therapy company.
Expanded clinical pipeline by combining three complementary cell therapy assets.
Significantly reduced cash burn by eliminating non-core activities.
Focused priorities and rebranded the company with a new leadership team, name, and headquarters in San Diego County.
Lineage
Lineage
Lineage Revenue by Segment
Forward Guidance
Lineage anticipates that net operational spend for 2020 will be approximately $16 million. Assuming the Juvenescence note is paid in cash at maturity, the Company believes that it is funded well into 2021 as a result of these cost savings initiatives.